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Cryptic physiological trophic support of motoneurons by LIF
revealed by double gene targeting of CNTF and LIF
M. Sendtner*†, R. Götz*†, B. Holtmann*†, J-L. Escary‡, Y. Masu†, P. Carroll†, 
E. Wolf§, G. Brem§, P. Brûlet‡ and H. Thoenen†
Background: The survival and differentiation of motoneurons during embryonic
development, and the maintenance of their function in the postnatal phase, are
regulated by a great variety of neurotrophic molecules which mediate their
effects through different receptor systems. The multifactorial support of
motoneurons represents a system of high security, because the inactivation of
individual ligands has either no detectable, or relatively small, atrophic or
degenerative effect on motoneurons.
Results: Leukaemia inhibitory factor (LIF) has been demonstrated to support
motoneuron survival in vitro and in vivo under different experimental conditions.
However, when LIF was inactivated by gene targeting, there were no apparent
changes in the number and structure of motoneurons and no impairment of their
function. The slowly appearing, relatively mild degenerating effects in
motoneurons that resulted from ciliary neurotrophic factor (CNTF) gene targeting
were substantially potentiated by simultaneous inactivation of the LIF gene,
however. Thus, in mice deficient in LIF and CNTF, the degenerative changes in
motoneurons were more extensive and appeared earlier. These changes were
also functionally reflected by a marked reduction in grip strength.
Conclusions: Degenerative disorders of the nervous system, in particular those
of motoneurons, may be based on multifactorial inherited and/or acquired defects
which individually do not result in degenerative disorders, but which become
apparent when additional (cryptic) inherited disturbances or sub-threshold
concentrations of noxious factors come into play. Accordingly, the inherited
inactivation of the CNTF gene in a high proportion of the Japanese population
may represent a predisposing factor for degenerative disorders of motoneurons. 
Background
There is rapidly accumulating evidence that the regula-
tion of motoneuron survival during embryonic develop-
ment, and the maintenance of their function in adulthood,
are mediated by a great variety of different molecules.
These molecules are produced by the motoneuron target
tissues, skeletal muscle, the Schwann cells which
ensheath the motoneurons (axons), and possibly by
orthograde trophic input from sensory and/or supraspinal
neurons [1–4].
Evaluation of the relative importance of the different neu-
rotrophic factors is the object of intense research using anti-
bodies, predominantly in chicks, and using transgenic
approaches, such as gene targeting and tissue-specific over-
expression in mice. Here, we report on double-knockout
experiments, in which the genes encoding ciliary neu-
rotrophic factor (CNTF) and leukaemia inhibitory factor
LIF) have been inactivated. The results of the experi-
ments reveal that LIF has a cryptic physiological neu-
rotrophic function which is not apparent in mice defective
in CNTF alone. This aspect is of particular interest in view
of the recent observation that a substantial proportion of
the Japanese population have a genetically determined
CNTF gene inactivation, which alone (not unexpectedly)
does not result in any clinical manifestations [5]. However,
these individuals might become more sensitive to
motoneuron degeneration by other damaging factors which
by themselves would not lead to degenerative changes
in motoneurons. The CNTF/LIF double-knockout
experiments represent a model for such a situation.
CNTF and LIF, which are members of a family of
cytokines, have no significant sequence homology but
exhibit similarities in their tertiary structure, which con-
tains four amphipathic helices [6–8]. This family includes
molecules that were identified by a variety of biological
activities (for review see [9]), such as induction of acute-
phase responses and B-cell stimulation (interleukin-6
(IL-6) and IL-11) [10], cytostatic effects on tumour cells
(LIF and oncostatin M/OSM), inhibition of embryonic
stem cell differentiation (LIF and CNTF), neuronal
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survival effects (CNTF), and induction of cardiac myocyte
hypertrophy (cardiotrophin-1) [11]. Further analyses
revealed that these factors share a variety of functions, such
as the support of motoneuron survival (CNTF and LIF)
[12,13], the induction of cholinergic differentiation of sym-
pathetic precursor cells (CNTF, LIF and OSM; summa-
rized in [14]) and initiation of acute-phase responses in
hepatic cells [9,10,15,16].
Apparently, these effects occur by activation of common
cellular receptor components. The effects of CNTF, LIF
[17], and most probably OSM [18], are mediated by a het-
erodimer composed of gp130, the signal-transducing com-
ponent of the IL-6 receptor, and LIFRb, which was first
identified as an essential signal-transducing component of
the LIF receptor [19]. These transmembrane molecules
share significant sequence homology, particularly in the
cytosolic domain [19], and form a low-affinity LIF and
CNTF receptor capable of initiating signal transduction
after ligand binding [20–22]. The physiological high-affin-
ity receptors for these ligands require at least one addi-
tional component [20,23]. The additional component(s)
that convert the low-affinity LIF receptor into a high-
affinity receptor are not yet known. In contrast, the high-
affinity binding of CNTF to its receptor is known to be
mediated by an extracellular CNTF-binding protein,
CNTFRa, which is expressed in neurons and skeletal
muscle cells [24]. This receptor component lacks a trans-
membrane domain and is linked by a glycosyl phosphatidyl
inositol anchor to the external lipid layer of the cell mem-
brane; but CNTFRa has also been found in soluble form
at substantial concentrations in the circulation and in the
cerebrospinal fluid [21].
CNTF is synthesized and located (at high concentrations)
in the cytosol of myelinating Schwann cells [25,26] and
subpopulations of astrocytes within the brain and spinal
cord. In contrast to LIF, CNTF lacks a hydrophobic
leader sequence, so it is not predicted to be released by
the classical secretory pathway from synthesizing cells.
Thus, the release of CNTF from Schwann cells after
nerve lesion is one possible means by which this molecule
can exert a function under pathophysiological conditions.
Indeed, CNTF immunoreactivity is detectable in the
extracellular space after lesion of the sciatic nerve of adult
rats [25]. Moreover, damage to the membrane of Schwann
cells could also occur after microtraumata, resulting in
permeability of the plasma membrane to proteins [27].
LIF mRNA is expressed at very low levels in the Schwann
cells of peripheral nerves. However, after nerve lesion, a
rapid and dramatic increase in LIF mRNA expression
occurs in the distal and proximal nerve stump in close
proximity to the lesion site [28]. This indicates that both
LIF and CNTF might become available to motor axons
after nerve lesion. In addition, retrograde transport of LIF
and CNTF, which seems to occur at very low levels in
peripheral nerves of adult rats, increases significantly after
peripheral nerve lesion [28,29].
Both CNTF [30] and LIF [31,32] are capable of rescuing
facial motoneurons from cell death after axotomy in
newborn rats. This indicates that both CNTF and LIF
have a protective effect on motoneurons, at least after
nerve lesion. In order to determine the physiological role
of these two cytokines for motoneurons, we have analyzed
mice lacking either CNTF or LIF, or lacking both factors,
for deficits in the motor system. Our data indicate that
both factors contribute to postnatal maintenance of
motoneurons. In addition, in adult mice lacking both
CNTF and LIF, the loss of motoneurons after nerve
lesion is greater than in mice deficient in CNTF alone.
These results indicate that, in the case of CNTF-
deficiency, the presence of LIF in the peripheral nervous
system prevents severe losses of neurons and impaired
neuronal function. These results may also have important
consequences for humans, because CNTF deficiency has
been reported to occur in at least 1–2 % of the Japanese
[5] and European populations (R. Giess and M. Sendtner,
unpublished observations).
Results
Inactivation of LIF gene expression does not lead to
degeneration of motoneurons
In order to compare CNTF and LIF knockout mice with
the same genetic background, we crossbred CNTF+/–
(129/SV × C57/BL6) mice with LIF+/– mice (129/SV ×
(c57Bl6 × DBA/2)) and investigated animals from the F2
generation which were either LIF–/–/CNTF+/+ or
LIF+/+/CNTF–/–. These mice were compared with control
LIF+/+/CNTF+/+ mice.
In agreement with results reported recently [33], LIF–/–
mice on this mixed genetic background did not show any
abnormalities of motor function or other behavioural
changes which could be attributed to defects of the
nervous system. In order to identify possible morphologi-
cal changes that were not sufficient to result in alterations
of motor behaviour in LIF–/– mice, we examined facial
motoneurons in paraffin sections from 4–8-week-old and
6–9-month-old LIF–/– mice. The facial nucleus was
chosen because it lacks interneurons, thus allowing an
accurate determination of motoneuron cell numbers by
morphological criteria. In contrast to mice lacking func-
tional CNTF expression, we did not observe any patho-
logical alterations in the LIF-deficient animals (Fig. 1a) at
the age of 9 months. CNTF–/– mice of the same age
showed degenerative changes, such as reduction of the
Nissl structure and atrophy of dendritic processes (Fig.
1b). The motoneurons appeared smaller, consistent with
previous observations [34]. Serial sections from the brain
stems of 6-week-old, 6-month-old and 9-month-old
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animals were prepared and the number of facial motoneu-
rons was determined. In contrast to CNTF–/– mice which
showed a 15 % reduction in the number of facial motoneu-
rons between postnatal week 4 and 6 months, there was
no reduction in facial motoneuron cell numbers in LIF–/–
mice at any age investigated (Table 1). 
Inactivation of both the CNTF and LIF genes leads to a
significant reduction of motoneurons 
Morphological analysis of CNTF–/–/LIF–/– mice at
6 months revealed significant pathological changes which
were comparable to those observed in CNTF–/– mice (Fig.
1c). Many motoneurons were severely atrophic and showed
complete loss of the Nissl structure; in addition, their
nuclei were relocated to sites close to the cell membrane
(see arrow in Fig. 1c). Such morphological changes were
already detectable in CNTF–/–/LIF–/– mice at 4–8 weeks
(Fig. 2). Determination of facial motoneuron numbers
revealed that the number of motoneurons was already
substantially reduced in the double-knockout mice at this
time point; in contrast, CNTF–/– mice did not yet exhibit
any significant loss of motoneurons (Table 1). In order to
distinguish whether this reduction in motoneuron number
was due to enhanced loss of motoneurons during postnatal
development, or to reduced generation during embryonic
Figure 1
Morphology of motoneurons in 6- to 9-month-old LIF–/–, CNTF–/– and
LIF–/–/CNTF–/– mice. (a) Facial motoneurons of a 9-month-old LIF–/–
mouse. (b) Facial motoneurons of a 6-month-old CNTF–/– mouse.
(c) Facial motoneurons of a 6-month-old CNTF–/–/LIF–/– mouse.
Motoneurons in 6-month-old CNTF–/– mice show a reduction of the Nissl
structure and an increase in the ratio between the nuclear and
cytoplasmic areas as described [34]. A significant number of
motoneurons in which Nissl structure was completely abolished are
detectable in CNTF–/–/LIF–/– mice. The nuclei of these cells appear
severely deformed and are located at an eccentric position very close to
the cellular membrane (arrow). In contrast, motoneurons in LIF-deficient
mice appear healthy and do not exhibit detectable signs of chromatolysis
or other degenerative changes. Scale bar: 25 µm.
Table 1
Number of facial motoneurons.
Genotype Age Number of facial
motoneurons
Wild-type 1 day 2397 ± 57 n = 4*
CNTF–/–/LIF–/– 1 day 2420 ± 96 n = 6* n.s.
Wild-type 4–8 weeks 2031 ± 132 n = 8†
CNTF–/– 4–8 weeks 2013 ± 135 n = 7†
CNTF–/–/LIF–/– 4–8 weeks 1604 ± 77 n = 9† p < 0.05
Wild-type 6 months 2128 ± 122 n = 6‡
CNTF–/– 6 months 1713 ± 104 n = 4‡
LIF–/– 6–12 months 2059 ± 71 n = 5‡
CNTF–/–/LIF–/– 6 months 1575 ± 54 n = 7‡ p < 0.05
Values shown are mean ± SEM of facial motoneuron counts corrected
for split nuclei as described [34]. Statistical significance was tested by
Student’s t-test and one-way ANOVA; the significance of the
differences (p values) between wild-type and CNTF–/–/LIF–/– mice is
shown in the last column. *The difference between 1-day-old wild-type
and CNTF–/–/LIF–/– animals was not statistically significant (n.s.). †The
differences between the three groups of mice at 4–8 weeks were
tested by one-way ANOVA: at the p < 0.05 levels, differences were
significant. Both the student’s t-test and Dunnet’s multiple comparison
test showed a significant difference between wild-type and
CNTF–/–/LIF–/– mice, and between CNTF–/– and CNTF–/–/LIF–/– mice,
but not between wild-type and CNTF–/– mice. ‡The differences
between the four groups of mice at 6–12 months were analyzed by
one-way ANOVA and found significant at the p < 0.005 level.
Comparison of individual groups either by Student’s t-test or Dunnet’s
multiple comparison test gave the following results: wild-type versus
CNTF–/–, p < 0.05; wild-type versus LIF –/–, n.s.; wild-type versus
CNTF–/–/LIF–/–, p < 0.05.
development, we determined the number of facial
motoneurons in newborn CNTF–/–/LIF–/– mice. We found
no reduction in the number of facial motoneurons in
1-day-old CNTF–/–/LIF–/– mice compared to wild-type
mice (Table 1), indicating that the loss of motoneurons
seen in the CNTF–/–/LIF–/– mice occurs exclusively
during postnatal development. 
Motor function is more severely impaired in CNTF–/–/LIF–/–
mice than in CNTF–/– mice
In order to evaluate whether the loss and morphological
alterations of motoneurons in CNTF–/–/LIF–/– mice were
reflected in a reduction of muscle strength, we measured
grip strength in these mice at different times after birth.
Recent analysis of muscle strength of CNTF–/– mice has
revealed that these mice do not develop a significant reduc-
tion in muscle strength (measured in Newtons, N) before
postnatal week 28 [34]. At that time, muscle strength was
reduced by around 10 % compared to wild-type mice. In
contrast, mice lacking both CNTF and LIF showed a
reduction in muscle strength of about 20 % at 4 weeks, and
a reduction of more than 30 % at 18 weeks (Fig. 3a). At this
time, average grip strength in mice deficient for both
CNTF and LIF was 0.87 ± 0.05 N, compared to
1.10 ± 0.1 N in mice deficient for LIF and 1.28 ± 0.07 N in
wild-type mice (Fig. 3b). At stages later than 18 weeks, a
similar reduction of grip strength was observed: at
6 months, grip strength in double-knockout mice (n = 9)
was 0.79 ± 0.06 N (mean ± SD) compared to 1.09 ± 0.14 N
in wild-type mice (n = 6), 0.95 ± 0.07 N in LIF–/– mice
(n = 3) and 0.94 ± 0.17 N in CNTF–/– mice (n = 9). At 9–12
months, grip strength in CNTF–/–/LIF–/– mice (n = 13)
was reduced to 0.67 ± 0.09 N. At this time the grip
strength of wild-type mice (n = 11) was 0.90 ± 0.14 N, in
LIF–/– mice (n = 2) 0.75 ± 0.11 N and in CNTF–/– mice
(n = 4) 0.74 ± 0.11 N. The differences between these
groups were statistically significant. The average body
weight of 18-week-old CNTF–/–/LIF–/– animals was
27 ± 1 g, and wild-type animals weighed 31 ± 2 g at the
same age. LIF-deficient animals did not show any reduc-
tion of body weight (31 ± 4 g) at this time point, nor was
there any evidence for significant differences at any other
time point between birth and 9 months of age (data not
shown). This shows that the reduced muscle strength
observed in CNTF–/–/LIF–/– animals is not a non-specific
consequence of body weight reduction, but is due to a
reduction in motoneuron numbers (and possibly impaired
function in  residual motoneurons).
The effect of lesion of the facial nerve in 4-week-old
CNTF–/– and CNTF–/–/LIF–/– mice
Both CNTF and LIF are capable of rescuing motoneurons
from massive degeneration after lesion of motor nerves in
newborn rats when they are applied locally at the lesion
site [30–32]. Motoneurons lose this high vulnerability to
lesion-induced degeneration during the 3 postnatal weeks,
and lesion of the facial nerve at 4 weeks of age does not
result in significant reduction of motoneurons within two
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Figure 2
Morphology of facial motoneurons in 6-week-old control, CNTF–/– and
CNTF–/–/LIF–/– mice. (a) Facial motoneurons of a 6-week-old control
mouse. (b) Facial motoneurons of a 6-week-old CNTF–/– mouse. (c) Facial
motoneurons of a 6-week-old CNTF–/–/LIF–/– mouse. Motoneurons in
6-week-old CNTF–/– mice were not yet reduced in number, but showed
reduced cytoplasmic area (b) in comparison to motoneurons of wild-type
mice (a). In contrast, severely atrophic motoneurons could already be
detected in 6-week-old CNTF–/–/LIF–/– mice (c). Scale bar: 40 µm.
weeks, particularly in mice of the genetic background
used in this study. We have proposed that the expression
of endogenous CNTF, which reaches maximal levels by
the end of the third postnatal week [35], might contribute
to the survival of motoneurons after lesion in adult animals
compared to newborns. 
In order to test this hypothesis, facial nerve transection
was carried out in CNTF–/– animals at 4 weeks, when
motoneurons have not yet been lost [34]. Motoneuron
numbers were determined 2 weeks later in paraffin serial
sections of the lesioned and contralateral sides of the
brain-stem region that contained the facial nuclei. After
facial nerve lesion in CNTF–/– mice, the number of facial
motoneurons on the lesioned side was still 90 % of that on
the control side (Table 2); the number in the latter was
not significantly different from that in wild-type mice.
This either indicates that motoneurons did not need
CNTF for their survival after lesion at age 4 weeks, or that
other factors, such as LIF, compensated for the lack of
CNTF. After peripheral nerve lesion, LIF expression is
rapidly upregulated within 24 hours, both in the proximal
and the distal nerve stump [28]. We therefore also deter-
mined motoneuron survival after lesion in CNTF–/–/LIF–/–
mice. In contrast to CNTF–/– mice, there was a significant
loss of motoneurons after lesion at 4 weeks of age. In com-
parison to the unlesioned side, 34 % of motoneurons were
lost, compared to 10 % in CNTF–/– mice. This result indi-
cates that LIF and CNTF cooperate in maintaining
motoneuron survival after lesion in 4-week-old mice.
LIF mRNA levels in the sciatic nerves of CNTF–/– mice
Previous studies have indicated that the levels of LIF
expression in peripheral nerves of adult rats are very low
[28,36]. We have now determined the levels of LIF
mRNA in mouse sciatic nerves in 4- and 12-week-old
animals. Initial northern blot analysis demonstrated that
the levels of LIF mRNA in unlesioned sciatic nerve were
so low that a reliable determination was not possible (as
reported previously in rat [28]). Therefore, we have used a
quantitative detection method based on the polymerase
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Figure 3
Forelimb grip strength and body weight of male control and
CNTF–/–/LIF–/– knockout mice. (a) Comparison of grip strength
between wild-type and CNTF–/–/LIF–/– mice at different postnatal ages.
(b) Comparison of grip strength between 18-week-old male mice of
different genotypes. (c) Comparison of body weight of male wild-type
and CNTF–/–/LIF–/– mice. Grip strength (in Newtons, N) was
determined as described previously for CNTF–/– mice [34]. Briefly,
mice were allowed to grip a triangular ring of an automated grip
strength meter (Columbus Instruments), and then were pulled away
until the grip was opened. In contrast to CNTF–/– mice which show
only about 10 % reduction in grip strength at age 28 weeks [34], the
grip strength of CNTF–/–/LIF–/– mice was already reduced by more
than 30 % at age 18 weeks. Values shown are means (± SD) from at
least six determinations per group. Statistical significance of the
differences between groups shown in (b) was tested by one-way
ANOVA. The groups were different at p < 0.0001. In order to compare
the individual groups, the data were further analyzed by Dunnet’s
multiple comparison test. The differences between wild-type and
CNTF–/–, wild-type and CNTF–/–/LIF–/–, and CNTF–/– and
CNTF–/–/LIF–/– mice were significant at the P < 0.05 level; the grip
strength measurements in CNTF–/– and LIF–/– mice were not
significantly different.
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chain reaction (PCR). In 100 ng total mRNA isolated from
4-week-old mouse sciatic nerves, 6.2 fg specific LIF
mRNA, corresponding to about 2 500 molecules, could be
detected. At the age of 12 weeks, lower, but still signifi-
cant, levels (4.8 fg specific LIF mRNA per 100 ng total
mRNA) were detected (Fig. 4). There was no difference
between CNTF–/– and wild-type mice. These data indi-
cate that no increase of LIF mRNA expression occurs in
Schwann cells at a time when motoneurons degenerated
in CNTF–/– animals. 
Discussion
In this study, we have compared the consequences of
inactivating the CNTF, LIF, and combined CNTF and
LIF genes on postnatal survival of motoneurons in mice.
We found no reduction in the numbers of motoneuron
cells in the facial nuclei of any of these mutant mice at
birth. In contrast to CNTF–/– mice, no loss of motoneu-
rons could be detected in LIF–/– animals during postnatal
development up to nine months. CNTF–/–/LIF–/– mice
showed distinct signs of facial motoneuron atrophy and
significant functional motor deficits at 6 months of age.
Furthermore, a significant reduction of motoneuron
numbers was already detectable at 4 weeks of age, at a
time when no loss was detectable in CNTF–/– animals
[34]. In CNTF–/– animals, lesion of the facial nerve at 4
weeks (when endogenous CNTF levels in Schwann cells
have reached maximal levels in control mice) resulted
only in small motoneuron losses, which did not reach the
level of statistical significance (p > 0.05). In contrast, more
than 30 % of motoneurons were lost during the two weeks
after lesion in CNTF–/–/LIF–/– mice. Thus, both CNTF
and LIF expression are important for postnatal survival
and maintenance of motoneurons. 
Both CNTF [12] and LIF [13] are potent survival factors
for isolated embryonic motoneurons. These observations
have been extended by analysis of the effects of CNTF and
LIF on motoneuron survival in vivo after lesion of motor
nerves in perinatal rats. The results of these studies showed
that CNTF [30], as well as LIF [31,32], could prevent
death of motoneurons after axotomy. This functional
overlap of CNTF and LIF is reflected by the fact that
they share gp130 and LIFRb as signal-transducing recep-
tor components in responsive cells. However, significant
differences exist between these two ligands with respect
to their specific physiological function for motoneurons. In
contrast to LIF, CNTF lacks a hydrophobic leader
sequence [35,37] and is not released from synthesizing
cells by the conventional secretory pathway. CNTF is
expressed at relatively high levels in myelinating Schwann
cells, and large quantities of CNTF protein are stored in
the cytoplasm of these cells. In unlesioned nerves, the
levels of CNTF released seem to be very low, and it is the
release of CNTF from Schwann cells that seems to limit
its availability to responsive neurons, rather than the
expression of CNTF mRNA. The levels of LIF mRNA in
unlesioned sciatic nerves of 4- and 12-week-old mice are
at least 50 times lower than those of CNTF mRNA. After
peripheral nerve lesion, CNTF immunoreactivity is
detectable for at least one week at extracellular sites
Table 2
Effect of facial nerve lesion on the number of facial
motoneurons in CNTF–/– LIF–/– mice.
Genotype Age Control side Side with lesion Percentage
change (%)
Wild-type 6 weeks 2051 ± 101 2374 ± 40 115 ± 5
(n = 5)
CNTF–/–/LIF+/+ 6 weeks 1878 ± 196 1687 ± 217 90 ± 10
(n = 4)
CNTF–/–/LIF–/– 6 weeks 1677 ± 216 1113 ± 143 66 ± 11
(n = 4)
The facial nerve was transected unilaterally at 4 weeks and the mice
were analyzed at 6 weeks of age. The differences in the ratios between
the lesion side and the control side in the three groups were tested by
one-way ANOVA and were found to be significant at the p < 0.05
level. Further analysis of the individual groups by Dunnet’s multiple
comparison test and by Student’s t-test showed that the difference
between wild-type and CNTF–/– mice was not significant, whereas the
difference between wild-type and double-knockout mice was
significant at the p < 0.05 level.
Figure 4
Quantitative analysis of LIF mRNA expression in the sciatic nerve of
CNTF+/+ and CNTF–/– mice. Total RNA was reverse-transcribed and
amplified by PCR in the presence or absence of a competitor RNA
standard that was identical to the LIF sequence apart from a small
deletion. Serial dilution of the competitor RNA in the presence of a
constant amount of tissue RNA allowed the determination of the
amount of LIF mRNA in sciatic nerve. In both CNTF/++ and CNTF–/–
sciatic nerves, equivalent PCR product yields were found at a
concentration of 0.5–2 fg of competitor RNA in sciatic nerves from
4- and 12-week-old mice, which corresponded to about 2 500 LIF
mRNA molecules per 100 ng total RNA. Values shown are the mean of
at least three determinations in each group; bars represent SD.
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within the nerve from where it might become available to
regenerating motoneurons [25]. This has led to the
hypothesis that the cytoplasmic CNTF in myelinating
Schwann cells serves as a lesion factor after its release is
initiated by the disintegration of the glial cell membrane.
Thus CNTF would become available immediately after
lesion, whereas LIF, whose basal expression is low but
increases after lesion [28], comes into play at later times.
Specific binding of CNTF to its whole receptor complex
is mediated by binding to CNTFRa (reviewed in [17,23]),
which is linked to the cell membrane via a glycosyl phos-
phatidyl inositol anchor and which also exists in soluble
form in body fluids. LIF does not bind to the CNTFRa
receptor and does not displace CNTF from this binding
site [38–40]. Interestingly, the concentration of LIF neces-
sary to promote half-maximal survival of isolated rat
motoneurons is in a range of 0.1–0.5 ng ml–1 [13], about 10
times higher than the concentrations of CNTF supporting
half-maximal survival of responsive rat neurons, and about
10–20 times higher than concentrations of LIF necessary
for half-maximal biological responses of LIF in the M1
cell line or in hepatoma cells [18,20,41]. In addition, the
effect of 10 mg of recombinant rat LIF on facial motoneu-
ron survival is lower than the effect of 5 mg recombinant
CNTF after facial nerve transection in newborn rats [31].
This raises the question of whether the putative additional
component of the LIF receptor functioning as a high-
affinity converter in the M1 cell line and in rat hepatoma
cells [42] is expressed in motoneurons. The existence of
such a binding protein can be deduced from studies on the
retrograde transport of both CNTF and LIF [28,29]. Ret-
rograde transport of both CNTF and LIF is extremely low
in unlesioned motoneurons but increases significantly
after nerve lesion. Interestingly, the retrograde transport of
CNTF in motoneurons can be blocked by a 20-fold excess
of LIF [29], whereas a 20-fold excess of CNTF cannot
block retrograde transport of LIF. The reason for this
striking discrepancy is still unclear but points to the exis-
tence of an additional receptor component for LIF in
motoneurons, which either cannot bind CNTF or is
expressed at such high levels that even 20-fold excess of
CNTF cannot effectively compete for the binding to LIF
receptors. This demonstrates that the functional CNTF
and LIF receptors are different in motoneurons.
The observation that elimination of a gene does not lead
to phenotypic alterations in mutant mice but becomes
functionally relevant when combined with inactivation of
a second, functionally related gene, is not without prece-
dence. For example, inactivation of either MyoD or Myf-5
does not lead to morphological or physiological abnormali-
ties in skeletal muscle development and function [43,44].
However, the expression of Myf-5 is increased 3.5-fold in
MyoD-mutant mice, and double inactivation of MyoD
and Myf-5 abolishes the formation of skeletal muscle in
mutant mice [45]. LIF mRNA is not upregulated in sciatic
nerves of CNTF knockout mice at 4 and 12 weeks after
birth (Fig. 4). Apparently, regulatory mechanisms (as
observed with Myf-5 mRNA in MyoD knockout mice) do
not occur in CNTF–/– mice. Nevertheless, a greater reduc-
tion in the number of motoneurons is detectable in
CNTF–/– LIF–/– mice compared to CNTF mutant mice.
This has important consequences for motor function: the
loss of muscle strength is significantly greater in
CNTF–/–/LIF–/– mice than in CNTF–/– mice. Thus, LIF,
although expressed only at low levels in peripheral nerves,
contributes to compensatory mechanisms that prevent
functional deficits in CNTF–/– mutant mice. Moreover,
after axotomy, the presence of LIF in the peripheral
nerves of 4-week-old mice seems to protect motoneurons
from degeneration to a significant extent.
These observations are also clinically relevant. A mutation
of the CNTF gene that leads to an inactive gene product
has been discovered both in healthy subjects and in people
with neurological disease [5]. This mutation is quite
common both in Japan and in the European population (R.
Giess and M.S., unpublished observations). About 2 % of
the population in Japan and Europe lack functional CNTF
expression but do not exhibit any neurological disorders.
This indicates that functional deficits, such as muscle
paralysis, do not occur, most probably because other gene
products, such as LIF, function in a compensatory manner.
It would be interesting to determine whether gene defects
for LIF exist in humans, and whether combined gene
defects of CNTF and LIF could cause motoneuron
disease. Such multigenic mechanisms are relevant, because
amyotrophic lateral sclerosis (ALS), the most common
form of human motoneuron disease, occurs sporadically in
more than 90 % of all cases and does not exhibit classical
Mendelian inheritance. Thus it might be interesting to
know whether combined defects of CNTF and LIF genes,
possibly also in combination with other gene defects or
epigenetic influences, play a pathogenic role in patients
with sporadic ALS. 
Conclusions
CNTF and LIF cooperate in the postnatal maintenance of
the structure and function of motoneurons. Inactivation of
the LIF gene leads neither to a loss of motoneurons nor to
a reduction in muscle strength. The inactivation of the
CNTF gene alone leads to a 20 % reduction in the
number of motoneurons and a borderline reduction in
muscle strength. However, the inactivation of both CNTF
and LIF genes leads to a more rapid and extensive degen-
eration of motoneurons (their numbers were reduced by
more than 25 %) and to a reduction of muscle strength of
more than 30 %. This indicates that degenerative disor-
ders of motoneurons in humans could be caused by similar
combinations of gene defects, which individually do not
lead to functional defects. The widespread polymorphism
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of the human CNTF gene, which results in an inactive
gene product, could therefore be a predisposing condition
for the development of motoneuron disease if it is com-
bined with other gene defects. The CNTF–/–/LIF–/–
mouse could therefore be a model for human motoneuron
disease of multigenic origin.  
Materials and methods
CNTF and LIF knockout mice
Mice with homologous recombination of the CNTF gene [34] were
crossbred with LIF–/– mice [46]. Initially, heterozygous mice of each
phenotype were crossbred, and the offspring analyzed for the individual
genotypes by Southern blot analysis of tail DNA as described [34,46].
Mice exhibiting the individual phenotypes analyzed in this study were
derived from animals of this F1 generation. 
Facial nerve transection 
Control CNTF–/– and CNTF–/–/LIF–/– mice (both 4 weeks old) were
deeply anaesthetized with ether. The skin behind the right ear was sec-
tioned, and the facial nerve was exposed at the foramen stylomas-
toideum and transected with fine scissors. The stumps were deflected,
and the skin wound was closed using silk (Ethicon 6-0). The effect of
the facial nerve transection was detectable by unilateral absence of
whisker movement. Fourteen days later, the mice were killed, perfused
and brain stems were processed as described below. 
Histological analysis
Mice were perfused with 4 % paraformaldehyde. The brain stem was
dissected, embedded in paraffin and serial sections (7 mm) were pre-
pared and processed as described [34]. After Nissl staining, the
number of neurons exhibiting clear Nissl structure and containing a
clearly detectable nucleolus was counted in every fifth section. This
number was corrected for double-counting of split nucleoli as
described previously [34]. 
Determination of LIF mRNA 
Total RNA was isolated from sciatic nerves of 4- and 12-week-old mice
according to Chomczynski and Sacchi [47] using Trizol reagent
(Gibco). The yield of RNA was quantified by UV spectrophotometry.
For reverse transcription a LIF-specific primer (5′–ACGGTACTT-
GTTGCACAGAC) was annealed at 70 °C to a 100 ng aliquot of the
RNA and the reaction was started by the addition of Superscript II
reverse transcriptase (Gibco) according to the manufacturer´s instruc-
tions. Similarly, tissue RNA was added individually to tubes containing
a serially decreasing amount of an RNA reference standard. The RNA
standard was identical to the LIF sequence, except for an internal dele-
tion of 81 bases, and functions as a competitor in the subsequent
PCR. It was synthesized by in vitro transcription with T7 RNA poly-
merase from a plasmid DNA template in which an 81 bp NcoI–SmaI
fragment in exon 3 of the LIF encoding sequence had been deleted. An
aliquot of the resulting cDNA was amplified in a standard PCR using
the forward primer 5′–ACCCTGTAAATGCCACCTG (located in exon
2) and the reverse primer 5′–CAACGACCATTGCTGAGGAGG
(located in exon 3 of the LIF gene). Thus the LIF cDNA transcribed
from tissue mRNA results in the amplification of a 378 bp fragment,
whereas the competitor RNA is 297 bp long. Because the concentra-
tion of the tissue RNA was kept constant in each tube, and the concen-
tration of the competitor was varied, the resulting PCR products were
at equimolar concentrations when both RNA hybridization signals were
of equivalent density in autoradiograms hybridized with the specific LIF
cDNA probe.
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